Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Zymeworks Inc.
< Previous
1
2
3
4
Next >
Zymeworks Announces Participation in Upcoming Investor Conferences
August 01, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
July 25, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
July 22, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks to Host Second Quarter Results Conference Call
July 21, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Plan to Become a Delaware Corporation
July 15, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
June 27, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
June 10, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conference
May 27, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
May 26, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
May 20, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 04, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
May 02, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
April 28, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
April 28, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks to Host First Quarter 2022 Results Conference Call
April 19, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
April 01, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
February 24, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
February 08, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
February 03, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
January 31, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Pricing of $100.0 Million Public Offering
January 26, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Proposed Public Offering
January 26, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
January 19, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
January 15, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
January 05, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
December 09, 2021
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
December 08, 2021
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
December 01, 2021
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.